脾氨肽对肺炎支原体感染致哮喘患者淋巴细胞亚群的影响研究

发布时间：2018-05-23 19:41

本文选题：肺炎支原体感染 + 哮喘发作　；参考：《中华医院感染学杂志》2017年21期

【摘要】：目的分析脾氨肽冻干粉口服治疗肺炎支原体(MP)感染所致哮喘发作患者的临床疗效,为MP感染哮喘发作患者临床治疗提供参考。方法选择2015年3月-2016年3月医院治疗的MP感染致哮喘发作患者108例,采用随机数字表法将患者分为对照组和试验组,每组54例,对照组患者采用常规对症治疗及抗菌药物治疗,试验组患者在对照组治疗方案基础上,加用脾氨肽冻干粉口服治疗,两组患者均连续治疗2周,比较两组患者入组、治疗后免疫球蛋白IgG、IgA、IgM、T淋巴细胞亚群CD3+、CD_4~+、CD_8~+ 、CD_4~+/CD_8~+ 变化情况,并评价两组患者的临床症状评分。结果治疗2周后,两组患者IgG、IgA较治疗前均升高,IgM较治疗前降低(P0.05),但试验组患者治疗后IgG、IgA高于对照组患者,IgM低于对照组患者(P0.05);两组患者治疗后CD3+、CD_4~+、CD_4~+/CD_8~+ 较治疗前升高(P0.05),CD_8~+ 较治疗前明显降低(P0.05),但试验组患者治疗后CD3+、CD_4~+、CD_4~+/CD_8~+ 高于对照组患者(P0.05),CD_8~+ 低于对照组患者(P0.05);两组患者治疗后哮喘临床症状评分均较治疗前有明显降低,但治疗后试验组哮喘临床症状评分明显低于对照组(P0.05)。结论脾氨肽冻干粉口服辅助治疗可有效降低MP感染致哮喘发作患者哮喘临床症状评分,改善患者T淋巴细胞亚群构成,提高患者免疫功能,对MP感染致哮喘患者的治疗具有较高的临床价值。
[Abstract]:Objective to analyze the clinical efficacy of spleen aminopeptide lyophilized powder in the treatment of asthma attack caused by MP infection, and to provide reference for the clinical treatment of MP infected asthma attack patients. Methods from March 2015 to March 2016, 108 patients with asthma caused by MP infection were divided into control group (n = 54) and experimental group (n = 54). The patients in control group were treated with routine symptomatic therapy and antimicrobial therapy. The patients in the experimental group were treated with spleen aminopeptide lyophilized powder orally on the basis of the treatment plan of the control group. The patients in both groups were treated continuously for 2 weeks. After treatment, the immunoglobulin IgG / IgA T lymphocyte subsets (CD3 / CD4 / CD8 / CD8 ~ +) were collected and the clinical symptom scores of the two groups were evaluated. Results after 2 weeks of treatment, The IgG IgA of both groups was higher than that before treatment, but the IgGG IgA of the patients in the trial group was higher than that of the control group after treatment, and that of the patients in the two groups was lower than that of the control group (P 0.05). After treatment, the levels of CD3 CD4 ~ / CD8 ~ in the patients of the two groups were higher than those before the treatment. After treatment, the patients in the trial group were significantly lower than those in the control group in terms of CD3 / CD4 / CD8- / CD8, and the clinical symptom scores of the two groups were significantly lower than those of the control group, and the clinical symptoms of the patients in the two groups were significantly lower than those in the control group. After treatment, the clinical symptom score of asthma in the trial group was significantly lower than that in the control group (P 0.05). Conclusion the oral adjuvant therapy of spleen aminopeptide lyophilized powder can effectively reduce the clinical symptom score of asthma patients with MP infection, improve the T lymphocyte subsets, and improve the immune function of the patients. The treatment of MP infection induced asthma has high clinical value.
【作者单位】：郑州大学附属洛阳中心医院呼吸内科;
【分类号】：R562.25

【相似文献】